October 14, 2015 | Israeli bio-medical company, Medgenics closed its secondary share offering, raising $46 million. The Galilee-based company opted to issue more shares after its share price climbed over 50% between January and September of this year. Currently, the company’s market capitalization is $236 million. Founded in 2000 and led by CEO Michael Cola, Medgenics is developing a technology platform called TARGT that will help to treat patients with rare and orphan diseases.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments